{
  "docId": "019dd923-5efe-75c0-8dfe-c33214992e60",
  "docSlug": "e4e961afe28a39dc",
  "documentTitle": "2026 Investor Deck",
  "authorId": "JPMorgan-IR",
  "authorName": "Summit Therapeutics",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 12,
  "pageCount": 15,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline framework to communicate upcoming clinical trial readouts and regulatory events.",
  "elementsJson": [
    "headline_text",
    "timeline_visual",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/12",
  "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60",
  "deckJsonHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60.json",
  "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Abbreviations: 2L=second-line; BLA=Biologics License Application; EGFRm=epidermal growth factor receptor mutant positive; NSCLC=non-small-cell lung cancer; nSQ=non-squamous; OS=overall survival; PD-1=programmed cell death protein 1; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; SQ=squamous; VEGF=vascular endothelial growth factor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee09e17d-530d-411b-ad14-d2dbe0db9316",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "image",
      "text": "Anti-VEGF / Anti-PD-1 antibody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c8fbc29-64b4-4d8b-beb3-f2cb5abeed2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.7,
        "x": 0.22,
        "y": 0.68
      },
      "kind": "list",
      "text": "1H27: HARMONI-3 nSQ: PFS data readout expected",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f450c55-fa1c-45ea-b21d-265a6c5f10c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.7,
        "x": 0.22,
        "y": 0.32
      },
      "kind": "list",
      "text": "1H26: HARMONI-3 SQ: Completion of enrollment expected",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c55b49aa-32a2-4ac6-a432-7c42a88781fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.7,
        "x": 0.22,
        "y": 0.46
      },
      "kind": "list",
      "text": "2H26: HARMONI-3 SQ: PFS, interim OS data readout expected; HARMONI-3 nSQ: Completion of enrollment expected; HARMONI: BLA Decision in 2L+ EGFRm NSCLC expected",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eceb37e6-ad1f-4cac-81fe-e17dc759a904",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.7,
        "x": 0.22,
        "y": 0.18
      },
      "kind": "list",
      "text": "1Q26: Further details beginning this quarter on new global Phase IIIs",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef0790cf-43b4-4b82-9e21-5df8316589f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Shaping the Path to Become a Commercial Entity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c81ff055-acc8-44f4-894c-349d8b55a000",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "a8348e99-574e-40f8-98ce-d3361b68504a",
      "evidence": "Chronological sequence of events presented in a list format.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180",
      "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential",
      "position": 0,
      "objective": "Highlighting the importance of timely progress in biopharma development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}